Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | HH30134 |
| Synonyms | |
| Therapy Description |
HH30134 is a multi-kinase inhibitor with activity against AXL, FLT3, and NTRKs, potentially resulting in decreased tumor cell growth (NCI Drug Dictionary). |
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| HH30134 | HH-30134|HH 30134 | AXL Inhibitor 30 FLT3 Inhibitor 69 Trk Receptor Inhibitor (Pan) 33 | HH30134 is a multi-kinase inhibitor with activity against AXL, FLT3, and NTRKs, potentially resulting in decreased tumor cell growth (NCI Drug Dictionary). |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT04746612 | Phase I | HH30134 | A Phase I Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of HH30134 in Patients With Advanced Solid Tumours | Terminated | AUS | 1 |